With an estimated compound annual growth rate (CAGR) of 12.8% during the projected period, the antibody therapy market share is expected to reach $700 billion by 2032, up from $186 billion in a report published by FMI. The study finds that the rising demand for Humira (adalimumab) proportionately reflects on the adoption of antibody therapy.
COVID-19 has caused the world to come to a halt. We know that this health crisis had a significant impact on businesses in all different types of businesses. The pandemic is expected to have an effect on almost every part of the economy. The healthcare industry had a big problem at the start of the supply chain.
Trade growth for monoclonal antibody (Mab) treatment has slowed down for the big players in the market. If you look at the information on monoclonal antibody therapy in the market, it's broken down into human monoclonal antibody, humanized antibody, a chimeric antibody, and murine monoclonal antibody treatment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze